CANCERS BRONCHIQUES NON A PETITES CELLULES AU STADE AVANCE |
|
|
Références |
Chimiothérapie |
Traitement |
Contrôle |
p |
||
|
n pts (% St IV) |
SM (sem) |
n pts (% St IV) |
SM (sem) |
|||
|
Cormier, 1982 |
MTX-ADR-CPA-CCNU |
20 (50) |
30 |
19 (47) |
8 |
S |
|
Rapp, 1988 |
I. CDDP-ADR-CPA |
43 (86) |
25 |
50 (90) |
17 |
S |
|
II. CDDP-VDS |
44 (82) |
33 |
||||
|
Ganz, 1989 |
CDDP-VBL |
31 (100) |
13 |
32 (100) |
20 |
NS |
|
Woods, 1990 |
CDDP-VDS |
97 (74) |
27 |
91 (57) |
17 |
NS |
|
Kaasa, 1991 |
CDDP-VP16 |
44 (100) |
36 |
43 (100) |
24 |
NS |
|
Quoix, 1991 |
CDDP-VDS |
24 (100) |
28 |
22 (100) |
10 |
S |
|
Cellerino, 1991 |
CPA-epirubicine-CDDP ~ MTX- VP16- CCNU |
62 (60) |
34 |
61 (57) |
21 |
NS |
|
Leung, 1992 |
CDDP-VP16+ radiotherapy |
42 (0) |
50 |
62 (0) |
35 |
S |
|
Cartei, 1993 |
CDDP-CPA-MMC |
52 (100) |
36 |
50 (100) |
17 |
S |
|
Crawford, 1996 |
Vinorelbine (Contrôle : 5FU) |
143 (100) |
30 |
68 (100) |
22 |
0,03 |
|
Thongprasert, 1999 |
I. CDDP-epirubicine-Ifo |
96 |
25 |
98 |
18 |
S |
|
II. CDDP- MMC- VBL |
93 |
35 |
||||
|
Cullen, 1999 |
MMC-Ifo-CDDP |
165 |
29 |
177 |
21 |
S |
|
Italian study, 1999 |
Vinorelbine |
76 |
28 |
78 |
21 |
0,03 |
|
Ranson, 2000 |
Paclitaxel |
79 |
29 |
78 |
21 |
0,037 |
|
Anderson, 2000 |
Gemcitabine |
150 |
24 |
150 |
25 |
0,84 |
|
Roszkowski, 2000 |
Docetaxel |
137 |
26 |
70 |
24 |
0,026 |
|
Spiro, 2004 |
à base de cisplatine (MIP, MVP, CDDP-VDS, CDDP-VNR) |
364 |
32 |
361 |
23 |
0,0006 |
Références
(1) Cormier Y, Bergeron D, La Forge J, Lavandier M, Fournier M, Chenard J et al. Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma. Cancer 1982; 50(5):845-849.
(2) Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK et al. Chemotherapy can prolong survival in patients with advanced non-small- cell lung cancer--report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6(4):633-641.
(3) Ganz PA, Figlin RA, Haskell CM, La Soto N, Siau J. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference? Cancer 1989; 63(7):1271-1278.
(4) Woods RL, Williams CJ, Levi J, Page J, Bell D, Byrne M et al. A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 1990; 61(4):608-611.
(5) Kaasa S, Lund E, Thorud E, Hatlevoll R, Host H. Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer. Cancer 1991; 67(10):2443-2447.
(6) Quoix E, Dietemann A, Charbonneau J, Boutin C, Meurice JC, Orlando JP et al. La chimiothérapie comportant du cisplatine est-elle utile dans le cancer bronchique non microcellulaire au stade IV ? Résultats d'une étude randomisée. Bull Cancer 1991; 78(4):341-346.
(7) Cellerino R, Tummarello D, Guidi F, Isidori P, Raspugli M, Biscottini B et al. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. J Clin Oncol 1991; 9(8):1453-1461.
(8) Leung WT, Shiu WC, Pang JC, Lau J, Tao M, Leung SF et al. Combined chemotherapy and radiotherapy versus best supportive care in the treatment of inoperable non-small-cell lung cancer. Oncology 1992; 49(5):321-326.
(9) Cartei G, Cartei F, Cantone A, Causarano D, Genco G, Tobaldin A et al. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer [see comments]. J Natl Cancer Inst 1993; 85(10):794-800.
(10) Crawford J, O'Rourke M, Schiller JH, Spiridonidis CH, Yanovich S, Ozer H et al. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J Clin Oncol 1996; 14(10):2774-2784.
(11) Thongprasert S, Sanguanmitra P, Juthapan W, Clinch J. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 1999; 24(1):17-24.
(12) Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R et al. Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non-Small-Cell Lung Cancer: Effects on Survival and Quality of Life. J Clin Oncol 1999; 17(10):3188-3194.
(13) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 1999; 91(1):66-72.
(14) Ranson M, Davidson N, Nicolson M, Falk S, Carmichael J, Lopez P et al. Randomized Trial of Paclitaxel Plus Supportive Care Versus Supportive Care for Patients With Advanced Non-Small-Cell Lung Cancer. J Natl Cancer Inst 2000; 92(13):1074-1080.
(15) Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 2000; 83(4):447-453.
(16) Roszkowski K, Pluzanska A, Krzakowski M, Smith AP, Saigi E, Aasebo U et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC) [In Process Citation]. Lung Cancer 2000; 27(3):145-157.
(17) Spiro SG, Rudd RM, Souhami RL, Brown J, Fairlamb DJ, Gower NH et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004; 59(10):828-836.
(18) Brown J, Thorpe H, Napp V, Fairlamb DJ, Gower NH, Milroy R et al. Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. J Clin Oncol 2005; 23(30):7417-7427.